WCM Investment Management LLC Has $14.47 Million Position in Repligen Co. (NASDAQ:RGEN)

WCM Investment Management LLC boosted its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 47.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 99,158 shares of the biotechnology company's stock after purchasing an additional 32,126 shares during the period. WCM Investment Management LLC owned 0.18% of Repligen worth $14,470,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Repligen by 0.4% during the first quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company's stock worth $937,994,000 after buying an additional 21,719 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Repligen by 21.0% in the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company's stock valued at $172,749,000 after purchasing an additional 237,884 shares during the last quarter. Conestoga Capital Advisors LLC lifted its stake in Repligen by 26.7% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company's stock valued at $119,363,000 after purchasing an additional 199,322 shares during the last quarter. Thrivent Financial for Lutherans lifted its holdings in shares of Repligen by 240.5% during the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company's stock worth $75,866,000 after buying an additional 425,061 shares in the last quarter. Finally, New York State Common Retirement Fund raised its stake in Repligen by 14.4% during the third quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company's stock worth $84,387,000 after acquiring an additional 71,274 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on RGEN shares. Wells Fargo & Company initiated coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 price objective on the stock. Stephens reissued an "overweight" rating and set a $170.00 target price on shares of Repligen in a research note on Tuesday, July 30th. UBS Group lowered their target price on Repligen from $205.00 to $185.00 and set a "buy" rating for the company in a report on Wednesday, July 31st. Royal Bank of Canada restated an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Finally, Benchmark reiterated a "hold" rating on shares of Repligen in a report on Monday, August 5th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Repligen presently has a consensus rating of "Moderate Buy" and an average price target of $190.25.

Insider Transactions at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the business's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 1.20% of the company's stock.

Repligen Trading Up 6.5 %

Shares of RGEN stock traded up $9.08 on Tuesday, hitting $148.59. The stock had a trading volume of 1,399,271 shares, compared to its average volume of 657,944. The firm has a market capitalization of $8.32 billion, a P/E ratio of -3,751.75, a P/E/G ratio of 4.04 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13. The company's 50 day moving average price is $141.34 and its 200-day moving average price is $144.87.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.